[Research Progress on Chemoresistance Mechanism of Nuclear Factor Kappa B Signalling Patheway in Acute Myeloid Leukemia].
Acute myeloid leukemia (AML) is the most common leukemia in adult, among them the childhood acute myeloid leukemia accounts for 15% to 20%. After exploring and investigating this disease for 60 years, the systematic chemotherapy can achieve complete remission for 75%-80% AML patients, but only 20%-30% AML patients out of them can be cured, and other AML patients relapsed or died of this disease. The primary and/or seondary chemotherapy resistance may be the main reasons of the poor prognosis in AML. The activity of nuclear factor kappa B (NF-κB) involved into multi-layers of physiological functions. Among them, the activity of NF-κB and the apoptosis toleration associated with the sensitivity to chemotherapy. All these indicated that the inhibition of NF-κB may be a promising direction to reverse chemoresistance and improve chemotherapeutic effects for AML. Herein is the review of recent research progress on the field of the roles of NF-κB activation in AML and its application in AML therapy.